SR9011 Capsule

The core functional mechanism of SR9011 capsule centers on the activation of REV-ERBα/β receptors. As pivotal nuclear receptors in the mammalian circadian rhythm regulatory network, REV-ERBα/β are widely distributed in the liver, skeletal muscle, adipose tissue, brain and immune cells, directly participating in key physiological processes including clock gene expression regulation, energy metabolism balance, inflammatory response and cell proliferation and differentiation. As a potent agonist, CS-2028 specifically binds to REV-ERBα/β receptors to enhance their transcriptional repressive activity, thereby exerting multiple physiological regulatory effects.

On one hand, CS-2028 directly inhibits the transcriptional expression of core clock genes BMAL1 and CLOCK, resets disrupted circadian rhythms and ameliorates biological clock disorders caused by staying up late, jet lag and other factors. On the other hand, REV-ERB receptor activation upregulates the expression of mitochondria-related genes, boosts mitochondrial quantity and oxidative respiratory function, elevates basal energy consumption, and modulates the activity of enzymes involved in glucose and lipid metabolism to achieve dual regulation of lipolysis and glucose metabolism balance. Moreover, CS-2028 suppresses the expression of key inflammatory pathway factors to alleviate chronic inflammation and inhibits the proliferation cycle of cancer cells, endowing CS-2028 with broad research potential across multiple fields.

1. Metabolic Regulation: Fat Loss, Glycemic Control and Lipid Modulation

In the field of metabolic regulation, CS-2028 exert prominent effects on fat reduction, blood sugar management and blood lipid adjustment, ranking among its most extensively studied core functions. In animal trials conducted on obese mice induced by high-fat diets, continuous administration of CS-2028 for 2 to 3 months led to substantial body weight reduction with a fat mass decrease of 10 to 15 pounds. CS-2028 primarily reduces harmful visceral fat without causing significant loss of skeletal muscle, realizing fat loss while preserving muscle mass.

Its fat-lowering mechanism lies in activating REV-ERB receptors to inhibit the activities of key enzymes such as fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1), curbing adipocyte synthesis and accumulation, and upregulating lipolysis-related genes to accelerate fat mobilization and oxidative decomposition, which markedly raises energy expenditure even at resting state.

For glucose metabolism regulation, the product improve insulin sensitivity, lower fasting blood glucose levels and relieve insulin resistance, presenting remarkable ameliorative effects on glycemic indicators in type 2 diabetic model animals.

Relevant studies confirm that CS-2028 maintains blood glucose homeostasis by regulating hepatic glycogen synthesis and decomposition, offering novel target directions for metabolic disorder research. Additionally, this formulation optimizes blood lipid profiles, effectively reducing serum triglycerides, total cholesterol and low-density lipoprotein (LDL) while elevating high-density lipoprotein (HDL), thus lowering potential risks of cardiovascular diseases such as atherosclerosis. Notably, CS-2028 is a non-hormonal compound. Unlike traditional selective androgen receptor modulators (SARMs), CS-2028 does not interfere with endogenous testosterone secretion, eliminating the need for post-cycle therapy (PCT), which constitutes a distinct advantage over analogous research compounds.

2. Exercise Performance Enhancement: Endurance Improvement and Recovery Acceleration

Enhancing athletic performance, boosting physical endurance and speeding up post-exercise recovery represent another vital function of the product. Multiple studies have verified its favorable efficacy in improving skeletal muscle function. By activating REV-ERB receptors, CS-2028 evidently increases the quantity and activity of mitochondria in skeletal muscle cells, strengthens oxidative metabolism capacity and elevates muscular oxygen utilization efficiency, consequently prolonging exercise duration and mitigating fatigue, functioning similarly to an endurance booster.

In animal locomotor experiments, mice administered with it achieved over 30% higher running endurance compared with the control group, accompanied by drastically reduced post-exercise lactic acid accumulation, relieved muscular soreness and a 20%-30% shorter recovery period. Such effects are mainly attributed to enhanced mitochondrial function. As the cellular energy powerhouse, activated mitochondria supply more energy for skeletal muscles and diminish metabolic waste buildup, thereby optimizing athletic performance and expediting physical recovery.

Furthermore, CS-2028 modulates muscular energy metabolism pathways to facilitate muscle fiber repair and growth, further augmenting muscle strength and endurance. Hence, CS-2028 is widely adopted in scientific researches concerning exercise physiology and muscle metabolism. It must be emphasized that despite its athletic performance-boosting properties, CS-2028 has not obtained approval for human clinical use and carries potential safety hazards, so illegal use by athletes is strictly prohibited.

3. Anti-Inflammation and Immune Modulation: Inflammation Relief and Immune Homeostasis Maintenance

In terms of anti-inflammatory and immunomodulatory effects, SR9011 capsule exert potent anti-inflammatory activities and regulate immune balance via targeted action on REV-ERB receptors. Chronic inflammation serves as a core pathogenic factor for numerous disorders including arthritis, obesity-associated inflammation and neuroinflammation, and REV-ERB receptors play an indispensable role in inflammatory response modulation.

By activating REV-ERBα/β, CS-2028 significantly downregulates the expression of pro-inflammatory mediators such as nuclear factor-kappa B (NF-κB), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and upregulates anti-inflammatory cytokines like interleukin-10 (IL-10), effectively alleviating chronic inflammatory conditions. In in vitro microglia experiments, CS-2028 markedly suppresses pro-inflammatory cytokine expression, inhibits mitochondrial respiration and ATP production, and weakens phagocytic activity, highlighting its critical role in the crosstalk between cerebral metabolism and immune functions.

Moreover, this formulation balances the differentiation of Treg/Th17 cells to mitigate autoimmune responses, providing innovative research perspectives for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, and is expected to uncover new therapeutic targets for such illnesses.

4. Anti-Tumor Potential: Targeted Inhibition of Cancer Cell Proliferation

The product also possess promising anti-tumor research prospects, which are mainly realized by restraining cancer cell proliferation and inducing cancer cell apoptosis to achieve targeted tumor suppression.

Researches demonstrate that CS-2028 activates REV-ERB receptors to inhibit cyclin A expression, blocking the transition of cancer cells from G0/G1 phase to S phase and G2/M phase and arresting cancer cells at the G0/G1 phase to halt their proliferation and division.

More importantly, CS-2028 exhibits highly selective cytotoxicity against cancer cells dependent on de novo lipogenesis, including breast cancer, liver cancer and lung cancer cells, while imposing minimal impacts on normal cells, making CS-2028 an ideal research tool compound for anti-tumor investigations. In addition, CS-2028 suppresses tumor angiogenesis and reduces inflammatory factors within the tumor microenvironment to further hinder tumor metastasis and invasion.

In in vivo tumor model experiments, oral administration of the product remarkably lowers tumor incidence rates and shrinks tumor volumes, laying experimental foundations for the development of novel anti-tumor therapeutic strategies.

5. Neuroprotection and Circadian Rhythm Regulation

The product also exert essential effects on neuroprotection and circadian rhythm regulation. Widely distributed in brain tissues, REV-ERB receptors participate in the modulation of circadian rhythms, sleep quality and neurological functions.

CS-2028 resets abnormal circadian rhythms to improve sleep deterioration triggered by jet lag and sleep disorders, stabilize biological clocks and restore regular daily routines.

Meanwhile, CS-2028 delivers potential neuroprotective effects by mitigating neuroinflammation and reducing beta-amyloid protein deposition to alleviate neuronal damage, opening up new research avenues for neurodegenerative diseases such as Alzheimer's disease. In addition, animal studies prove that CS-2028 can enhance physical fitness and locomotor ability in elderly individuals and extend healthspan (referring to disease-free healthy lifespan rather than overall lifespan), offering crucial research tools for aging-related scientific explorations.